540|118|Public
25|$|TTR misfolding and {{aggregation}} {{is known}} {{to be associated with the}} amyloid diseases senile <b>systemic</b> <b>amyloidosis</b> (SSA), familial amyloid polyneuropathy (FAP), and familial amyloid cardiomyopathy (FAC).|$|E
500|$|While PrP is {{considered}} the only mammalian prion, prion-like domains {{have been found in}} a variety of other mammalian proteins. Some of these proteins have been implicated in the ontogeny of age-related neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS, known as Motor Neurone Disease outside the US), [...] frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U), Alzheimer's disease, and Huntington's disease, as well as some forms of <b>Systemic</b> <b>Amyloidosis</b> including AA (Secondary) Amyloidosis that develops in humans and animals with inflammatory and infectious diseases such as Tuberculosis, Crohn's disease, Rheumatoid arthritis, and HIV AIDS. AA amyloidosis, like prion disease, may be transmissible. [...] This has given rise to the 'prion paradigm', where otherwise harmless proteins can be converted to a pathogenic form by a small number of misfolded, nucleating proteins.|$|E
50|$|Haemodialysis-associated {{amyloidosis}} {{is a form}} of <b>systemic</b> <b>amyloidosis</b> {{associated with}} chronic kidney failure.|$|E
40|$|Dysphagia, sicca syndrome, chronic non-infectious {{diarrhoea}} – dominant {{symptoms of}} <b>systemic</b> AL <b>amyloidosis</b> A case report <b>Systemic</b> AL <b>amyloidosis</b> is a disorder characterized by accumulation of insoluble fibrillar protein in beta pleated sheet configuration, {{which is called}} amyloid, in the tissues. Accumulation of amyloid occurs extra-cellulary and initially perivascular deposition can be found. In <b>systemic</b> AL <b>amyloidosis</b> monoclonal Ig light chains, usually of lambda type, secreted by abnormal clones of plasma cells, are the precursors of amyloid. These soluble light chains (or their fragments) circula-te in the bloodstream, then {{move out of the}} blood ves...|$|R
40|$|Bone {{involvement}} {{in patients with}} <b>systemic</b> AL <b>amyloidosis</b> mimics lytic myeloma bone disease The definition of organ {{involvement in}} <b>systemic</b> AL <b>amyloidosis</b> has been recently published and a consen-sus conference has defined major criteria for 7 main organ systems. 1 However, bone disease was not includ-ed {{in the list of}} affected organs and has not yet been systematically studied. It has been diagnosed rarely after emergency surgery of the spine. 2, 3 Using the Salmon and Durie classification 4 patients with monoclonal gammopathy (MG) and osteolytic bone lesions in X-ray are diagnosed as multiple myelo-ma (MM) stage III. Differentiation between MG or MM as the underlying disease of AL amyloidosis might have significant therapeutic consequences...|$|R
40|$|Nonhematologic {{malignancies}} {{are rarely}} {{reported to be}} associated with AA amyloidosis. Although the association between renal cell carcinoma and <b>systemic</b> AA <b>amyloidosis</b> has been established, the evidence linking pulmonary cancer to AA amyloidosis is scarce. Here, a case of biopsy-proven renal AA amyloidosis complicated with nephrotic syndrome associated with lung carcinoma is reported...|$|R
5000|$|... "FAP-I" [...] and [...] "FAP-II" [...] are {{associated}} with transthyretin. (Senile <b>systemic</b> <b>amyloidosis</b> is also associated with transthyretin aggregation.) ...|$|E
50|$|Senile <b>systemic</b> <b>amyloidosis</b> was {{determined}} to be the primary cause of death for 70% of people over 110 who have been autopsied.|$|E
5000|$|... type III is also {{described}} {{which has an}} onset at age 70 to 90 years and is not associated with <b>systemic</b> <b>amyloidosis.</b>|$|E
40|$|The case is {{reported}} {{of a patient}} with <b>systemic</b> AA <b>amyloidosis</b> associated with non-specific mesenteric lymphadenitis and chronic sideropenia. Renal, small bowel, and rectal biopsies showed amyloid deposits containing AA protein, as defined by potassium permanganate sensitivity and by reactivity with AA antiserum. Reversal of the nephrotic syndrome occurred during steroid-azathioprine therapy...|$|R
40|$|International audienceImmunoglobulin M (IgM) -related {{amyloidosis}} {{remains a}} rare and little-known complication of monoclonal IgM-associated disorders. We sought to determine the clinical and laboratory presentation, response to treatment, and outcome of patients with IgM-related amyloidosis {{in the era of}} new therapeutic approaches. We conducted a retrospective study in 29 French centers to identify patients with monoclonal IgM and biopsy-proven amyloidosis; we reviewed patients' records and collected relevant clinical and laboratory data. We identified 72 patients with IgM-related <b>amyloidosis.</b> <b>Systemic</b> primary <b>amyloidosis</b> (AL) was present in 64, peritumoral AL in 5, and <b>systemic</b> secondary <b>amyloidosis</b> (AA) in 3 patients. A peculiar pattern of relatively frequent lymph node (31 %) and lung (17 %) involvement was noted in patients with <b>systemic</b> AL <b>amyloidosis.</b> Response to alkylating agents was poor, with a hematologic response in 37 %, a complete remission in 0 %, and an organ response in 21 %. Response to hematopoietic stem cell transplantation showed a hematologic response in 100 % with complete remission in 75 % and an organ response in 75 %. Purine analogs and rituximab induced a hematologic response in 73 % and 60 %, respectively, with complete remission in 9 % and 0 % and an organ response in 55 % and 0 %, respectively. In multivariate analysis, prognostic factors for survival were serum albumin level < or = 3. 5 g/dL (p = 0. 018) and heart involvement (p = 0. 0034). Further prospective studies are needed in patients with IgM-related amyloidosis, with special emphasis on treatment options: hematopoietic stem cell transplantation and purine analogs could represent the most effective therapies. The identification of adverse prognostic factors of survival could be useful for those managing and making treatment decisions for these patients...|$|R
40|$|Cryopyrin-associated {{periodic}} syndromes (CAPS) are a {{group of}} chronic, relapsing autoinflammatory disorders which may be complicated by <b>systemic</b> AA <b>amyloidosis.</b> The aim of our study was to evaluate serum amyloid protein A (SAA) level in CAPS patients treated with Interleukin- 1 beta (IL- 1 β) antagonist and to correlate its level with treatment response...|$|R
50|$|Primary <b>systemic</b> <b>{{amyloidosis}}</b> (AL amyloidosis or just primary amyloidosis) is {{a disease}} that involves the mesenchymal tissue, the tongue, heart, gastrointestinal tract, and skin.|$|E
5000|$|Secondary (reactive) amyloidoses {{occur as}} a {{complication}} of some other chronic inflammatory or tissue-destroying disease. Examples are reactive <b>systemic</b> <b>amyloidosis</b> and secondary cutaneous amyloidosis.|$|E
5000|$|Amyloid light-chain (AL) {{amyloidosis}}, primary <b>systemic</b> <b>amyloidosis</b> (PSA) or just primary amyloidosis is {{the most}} common form of <b>systemic</b> <b>amyloidosis</b> in the US. The disease is caused when a person's antibody-producing cells do not function properly and produce abnormal protein fibers made of components of antibodies called light chains. These light chains come together to form amyloid deposits which can cause serious damage to different organs. Abnormal light chains in urine are sometimes referred to as [...] "Bence Jones protein".|$|E
50|$|It is a {{cofactor}} for lecithin cholesterolacyltransferase (LCAT) {{which is}} responsible for the formation of most plasma cholesteryl esters. Apo A1 was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with <b>systemic</b> non-neuropathic <b>amyloidosis.</b>|$|R
50|$|There are {{currently}} no approved treatments for <b>systemic</b> AA <b>amyloidosis.</b> The current {{standard of care}} includes treatments for the underlying inflammatory disease with anti-inflammatory drugs, immunosuppressive agents or biologics. AA amyloidosis patients are also receiving treaments {{to slow down the}} decline of their renal function, such as angiotensin II receptor blockers or angiotensin converting enzyme inhibitors.|$|R
40|$|A European {{collaborative}} study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of <b>systemic</b> AL <b>amyloidosis.</b> Blood. 2015; 126 (5) : 612 - 615. 2. Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term {{results in a}} series of 421 patients. Blood. 2011; 118 (16) : 4346 - 4352. 3. Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014; 99 (4) : 743 - 750. 4. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary <b>systemic</b> (light chain) <b>amyloidosis.</b> J Clin Oncol. 2010; 28 (6) ...|$|R
5000|$|... type II or Finnish type amyloidosis: {{associated}} with manifestations of <b>systemic</b> <b>amyloidosis</b> due to accumulation of gelsolin. Associated conditions may include cutis laxa and ataxia.|$|E
50|$|TTR misfolding and {{aggregation}} {{is known}} {{to be associated with the}} amyloid diseases senile <b>systemic</b> <b>amyloidosis</b> (SSA), familial amyloid polyneuropathy (FAP), and familial amyloid cardiomyopathy (FAC).|$|E
50|$|Amyloid purpura {{affects a}} {{minority}} of individuals with amyloidosis. For example, purpura is present early in the disease in approximately 15% of patients with primary <b>systemic</b> <b>amyloidosis.</b>|$|E
40|$|A case is {{reported}} of a 21 year {{old woman who}} suffered from Castleman's disease and <b>systemic</b> reactive <b>amyloidosis.</b> The serum concentrations of serum amyloid A (SAA) and interleukin 6 (IL- 6) were extremely high and amyloid protein was immunohistochemically identified as AA. After surgical excision of a large retroperitoneal lymph node with the pathological findings of plasma cell type of Castleman's disease, both serum SAA and IL- 6 declined, showing a similar pattern of reduction curves. All clinical symptoms and laboratory abnormalities greatly improved. The biochemical feature of Castleman's disease is abnormal production of IL- 6 and this cytokine continuously may stimulate the synthesis of an amyloid precursor, SAA, causing <b>systemic</b> reactive (AA) <b>amyloidosis.</b> This pathogenetic theory is strongly supported by the present study...|$|R
40|$|We {{report the}} first case of a 32 -year-old woman with Muckle–Wells {{syndrome}} and biopsy-proven <b>systemic</b> AA <b>amyloidosis</b> and end-stage renal disease. She was treated with canakinumab 150 mg subcutaneously every 8 weeks and underwent renal transplantation. Fourteen months after renal transplanation, the patient had no flares of Muckle–Wells syndrome and no evidence of amyloi-dosis in the renal transplant under an excellent graft func-tion and therapy with canakinumab...|$|R
40|$|<b>Systemic</b> AA <b>amyloidosis</b> {{is a rare}} {{complication}} of benign tumours. This report describes a patient with hepatocellular adenoma associated with reactive AA amyloidosis. He had a nephrotic syndrome with deteriorating renal function and an increase of serum concentrations of acute phase proteins, mainly C-reactive protein. Resection of the tumour was followed by improvement in renal function and a marked decrease of the serum concentrations of acute phase proteins...|$|R
50|$|Senile <b>systemic</b> <b>amyloidosis,</b> {{resulting}} from accumulation of aggregated wild-type transthyretin {{as part of}} the degenerative aging process, is emerging as an important and underdiagnosed contributor to HFpEF with age.|$|E
50|$|For chronic adrenal insufficiency, {{the major}} {{contributors}} are autoimmune adrenalitis (Addison's Disease), tuberculosis, AIDS, and metastatic disease. Minor causes of chronic adrenal insufficiency are <b>systemic</b> <b>amyloidosis,</b> fungal infections, hemochromatosis, and sarcoidosis.|$|E
50|$|Secondary <b>systemic</b> <b>amyloidosis</b> is a {{condition}} that involves the adrenal gland, liver, spleen, and kidney {{as a result of}} amyloid deposition due to a chronic disease such as Behçet's disease, ulcerative colitis, etc.|$|E
40|$|We {{report this}} {{case of a}} 42 -year-old woman who {{presented}} with a debilitating illness manifested by intractable nausea, vomiting, diarrhea and unchecked weight loss. The patient had multisystem involvement that presented as anemia, abnormal liver function tests and progressively deteriorating renal function necessitating dialysis. She {{was found to be}} profoundly hypoalbuminemic secondary to malabsorptive and protein-losing enteropathy in tandem with nephrotic range proteinuria. Intolerance to enteral feeding led the patient to be dependent on parenteral nutrition. Serum immunofixation revealed IgG lambda monoclonal protein. The patient underwent endoscopic evaluation with biopsies taken from the gastrointestinal tract that confirmed the diagnosis of primary <b>systemic</b> light-chain <b>amyloidosis.</b> A subsequent bone marrow biopsy revealed normocellular bone marrow with deposition of amyloid. The patient was not considered for autologous stem cell transplantation as the outcomes in patients with multisystem involvement are often poor, with a high mortality risk. Diffuse primary <b>systemic</b> light-chain <b>amyloidosis</b> involving the gastrointestinal tract is a rare entity and is to be considered among differentials in patients presenting with unexplained malabsorptive symptoms...|$|R
5000|$|In {{a healthy}} individual, the median plasma {{concentration}} of SAA is 3 mg per liter. This can increase to over 2000 mg per liter during an acute phase response and a sustained overproduction of SAA {{is required for}} the creation of the AA deposits that define AA amyloidosis. [...] High levels of SAA, however, is not a sufficient condition for the development of <b>systemic</b> AA <b>amyloidosis</b> and it remains unclear what triggers the accumulation of AA.|$|R
40|$|Background: Cutaneous {{amyloidosis}} {{has been}} classified into primary cutaneous amyloidosis (PCA, OMIM # 105250), secondary cutaneous <b>amyloidosis</b> and <b>systemic</b> cutaneous <b>amyloidosis.</b> PCA is the deposition of amyloid in previously apparent normal skin without <b>systemic</b> involvement. <b>Amyloidosis</b> cutis dyschromica (ACD) {{is a rare}} distinct type of PCA. Here, the unique clinical and histological findings of two Chinese female siblings with ACD were described. Cases presentations: Patient 1 was a 34 -year-old female, presented with mildly pruritic, diffuse mottled hyperpigmentation and hypopigmentation. The lesions involved all over the body since she was 10 years old. There were a few itchy blisters appearing on her arms, lower legs and truck, especially on the sun-exposed areas in summer. Some hypopigmented macules presented with slight atrophy. Patient 2 was 39 -year-old, the elder sister of patient 1. She had similar skin lesions since {{the same age as}} the former. The atrophy and blisters on the skin of the patient with amyloidosis cutis dyschromica have not been described in previous literature. Histological examinations of the skin biopsies taken from both patients revealed amyloid deposits in the whole papillary dermis. Depending on the histological assessment, the two cases were diagnosed as amyloidosis cutis dyschromica...|$|R
50|$|Organ-limited {{amyloidosis}} is {{a category}} of amyloidosis where the distribution can be associated primarily with a single organ. It is contrasted to <b>systemic</b> <b>amyloidosis,</b> {{and it can be}} caused by several different types of amyloid.|$|E
5000|$|In {{the elderly}} population, amyloid angiopathy is {{associated}} with cerebral infarcts as well as hemorrhage in superficial locations, rather than deep white matter or basal ganglia. These are usually described as [...] "lobar". These bleedings are not associated with <b>systemic</b> <b>amyloidosis.</b>|$|E
50|$|Born in New Brunswick, NJ, Carter {{graduated}} in 1974 from Highland Park High School and began attending the Berklee College of Music, {{where he studied}} percussion. In 1976, he returned to New Jersey {{to play with the}} dance band Network. He died in November 2006 from primary <b>systemic</b> <b>amyloidosis,</b> an incurable bone marrow disease.|$|E
40|$|Patients {{with primary}} immunodeficiencies (PID) are {{currently}} at low {{risk for the}} development of <b>systemic</b> reactive AA <b>amyloidosis.</b> A patient with common variable immunodeficiency and nephrotic syndrome was referred to our Clinic from a Nephrology unit. She had a history of recurrent infections. Monthly intramuscular immunoglobulin substitution treatment was started in 1979, subsequently switched to intravenous route. Between 1984 and 2007, she continued to experience infections and did not have follow-up visits in an Immunology Centre. Replacement therapy was discontinued in 2008 for adverse events related to IVIG infusion; since then she was admitted for recurrent cellulitis, sepsis, and pneumonia. In 2009, the patient developed massive proteinuria and renal failure due to clinically overt reactive <b>systemic</b> AA <b>amyloidosis.</b> Despite the prompt resumption of antibody replacement, adequate IgG levels were not achieved and SAA concentration remained elevated. Delay in diagnosis and inadequate treatment of PIDs results in increased irreversible complications, including AA amyloidosis...|$|R
50|$|Nephrogenic DI (NDI) is {{most common}} in its {{acquired}} forms, meaning that the defect was not present at birth. These acquired forms have numerous potential causes. The most obvious cause is a kidney or <b>systemic</b> disorder, including <b>amyloidosis,</b> polycystic kidney disease, electrolyte imbalance, or some other kidney defect.|$|R
40|$|We {{report an}} 18 year old black woman who {{presented}} with nephrotic syndrome in whom the investigations {{led to the}} diagnosis of diffuse Takayasu's disease, renal amyloidosis of AA type and interstitial lung disease. Proteinuria in Takayasu's disease is usually ascribed to hypertension or more rarely to glomerulonephritis. This case suggests that amyloidosis should be considered also {{in the investigation of}} proteinuria in these patients in view of the serious prognostic implications. This case represents further evidence that Takayasu's disease can be the cause of <b>systemic</b> reactive <b>amyloidosis</b> which may also be the presenting feature...|$|R
